Pavan Krishnamurthy

Pavan has over 15 years of research experience in the Alzheimer’s disease and tauopathy fields. He performed his graduate studies in Neuroscience in Kings College, London, and then University of Alabama. He began his work into developing novel therapeutics for AD, focusing on targeting the protein tau, in the labs of Prof. Karen Duff at Columbia University (New York) and then with Prof. Einar Sigurdsson, the pioneer of tau immunotherapy, at NYU Langone Medical Center, New York. Pavan then joined Oligomerix, Inc., a start-up biotech company in New York, to further their highly novel technology on targeting tau oligomers as a therapy. He has published and presented at national and international research conferences and has been the recipient of research grants from the Alzheimer’s Association as well as NIH.